*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# The United Laboratories International Holdings Limited

# 聯邦制藥國際控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

## SUPPLEMENTAL ANNOUNCEMENT TO 2025 ANNUAL REPORT

Reference is made to the annual report of The United Laboratories international Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") for the year ended 31 December 2025 (the "**2025 Annual Report**") published on 29 April 2026. Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meaning as those defined in the 2025 Annual Report.

The Company would like to supplement the following information in relation of the continued connected transactions with Muyuan Foods for the year ended 31 December 2025 (the "**Transactions**").

One of the Suppliers, Henan Lianmu Veterinary Medicine Co., Ltd., is owned as to 60% and 40% by the Company and Muyuan Foods, respectively. Muyuan Foods is therefore a connected person of the Company at subsidiary level pursuant to Chapter 14A of the Listing Rules. Accordingly, the transactions contemplated under the master sales agreement dated 3 June 2024 (the "**Master Agreement**") and the related annual caps constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The independent non-executive directors of the Company have reviewed the Transactions and confirmed the Transactions have been entered into: (1) in the ordinary and usual course of the business of the Group; (2) on normal commercial terms or better; and (3) according to the Master Agreement governing the Transactions on the terms that were fair and reasonable and are in the interest of the shareholders of the Company as a whole.

The Company's auditor was engaged to report on the Transactions in accordance with Hong Kong Standard on Assurance Engagement 3000 (Revised) "Assurance Engagements Other than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 (Revised) "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the HKICPA. The auditor has issued an unqualified letter confirming that nothing has come to its attention that caused it to believe that the Transactions: (1) have not been approved by the Board; (2) for the transactions involving the provision of goods and services by the Group, were not, in all material respects, in accordance with the pricing policies of the Group; (3) were not entered into, in all material respects, in accordance with the Master Agreement governing the Transactions; and (4) have exceeded the annual cap as set out by the Company.

The Company confirms that it has complied with the disclosure requirements in accordance with Chapter 14A of the Listing Rules.

The above supplemental information does not affect other information contained in the 2025 Annual Report. All other information in the 2025 Annual Report remains correct and unchanged.

By Order of the Board
**The United Laboratories International Holdings Limited**
Tsoi Hoi Shan
*Chairman*

Hong Kong, 27 August 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.